Novavax, Inc. (NASDAQ:NVAX) recently reported about its Q4 2016 in September 2016. The company’s EPS or earnings per share, stood at $-0.24/Share. The collective analysts’ estimate was $-0.26/Share, which means that the $0.02 difference was found.
Analysts counting on Novavax, Inc.
According to the analysts, the company’s Revenue Estimates for the present quarter can be as close to $5.45 Million. The high and low forecasts were created at $9 Million & $3.5 Million, respectively. The analysts are giving Novavax, Inc. a prospect to redeem itself, despite a salvaging year throughout. It still has the revenue potential to bounce back.
While several researchers have updated or revised their call for company, the question is, will Novavax, Inc. bounce back in 2017? Is it possible for the company to keep tanking and salvaging?
Healthcare Conference due- What to expect from Novavax, Inc.?
The company is about to present in the JP Morgan Healthcare Conference on 12 January 2017. The investors will closely watch the company since there is a lot mounting on the declarations to be made there.
Novavax, Inc., which specializes in proprietary recombinant nanoparticle vaccines, may have a few announcements to make. The conference will therefore play a vital role. With Pharma and drugmakers trying to pull up their socks in 2017, Novavax, Inc will have to work towards its USP.
Falling shares over 2016- Will 2017 be better?
Until the end of 2016, the company’s shares had been dwindling in the market. In the middle of November 2016, they had fallen over 17%, at some point of time. The company cannot afford a fall of this level in 2017.
With its Matrix-M™ adjuvant technology, the company can provide vaccines for some of the dreaded and chronic conditions. There shall be a close watch on the company as to what lies in the road ahead. Will there be more to 2017? Will the shares bounce back? The answers to the questions lie hidden somewhere in the tunnel that leads to the times to come or company’s strategic proposals for 2017.